Integrating MOUD in African American Community Settings (Better Together)

Launched by HOWARD UNIVERSITY · May 14, 2024

Keywords

ClinConnect Summary

This multi-site hybrid Type 1 effectiveness-implementation study conducted in Washington, District of Columbia (DC), Chicago, and Miami-Dade County will evaluate: 1) the effectiveness of providing MOUD with buprenorphine onsite (via telemedicine from a hub buprenorphine clinic) combined with Recovery Guiding in nonmedical community-based settings (the Better Together Integrated Collaborative Community MOUD care model - BT-MOUD) compared to standard-of-care MOUD with buprenorphine provided in the hub buprenorphine clinic only (HC-MOUD Only) and 2) BT-MOUD implementation barriers and facilita...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Be 16 years of age or older, as documented by self-report and verified by staff at the hub buprenorphine clinic.
• • 2. Self-identify race as Black (or African American, African, or Afro-Caribbean) (self report)
• • 3. Meets the Diagnostic Statistical Manual (DSM) -5 diagnostic criteria for current moderate or severe OUD, based on clinical evaluation by a hub clinic buprenorphine provider and documented in the hub clinic medical record.
• • 4. Be seeking, interested in receiving, and suitable for MOUD with buprenorphine, based on clinical evaluation by a hub clinic buprenorphine provider and documented in the hub clinic medical record.
• • 5. Have not received MOUD in the 30 days prior to enrolling in MOUD in the hub buprenorphine clinic (based on Prescription Drug Monitoring Program \[PDMP\] and self-report)
• • 6. Willing and able to provide informed consent, and when applicable, signed assent (consent process)
• • 7. Speak English well enough to be able to comprehend the study procedures and complete the assessments.
• Exclusion Criteria:
• • 1. Have significant cognitive or developmental impairment to the extent that they are unable to provide informed consent/assent.
• • 2. Have a psychiatric, cognitive, or medical condition which would make participation inappropriate or contraindicated, as assessed by the hub buprenorphine clinic provider.
• • 3. Plan to move out of the area or do not anticipate being able to remain in the study for 6 months.
• • 4. Are unable or unwilling to provide reliable locator information.
• • 5. Are currently in jail, prison, or other overnight facility as required by a court of law or have pending legal action that could prevent participation in study activities.
• • 6. They have previously enrolled in Clinical Trials Network (CTN) Protocol-0144 or are currently enrolled in another clinical trial for treatment of OUD.

Trial Officials